Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Investigator's choice of Chemotherapy · 1 trial · 1 indication
Time from randomization to the first documented tumor progression (per RECIST v1.1) or death from any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Arm A Azenosertib 400 mg administered daily on a 5 days on, 2 days off intermittent schedule | EXPERIMENTAL | - |
| Experimental: Arm C Investigator's choice of chemotherapy at the dose defined by the protocol | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Investigator's choice of Chemotherapy | DRUG | The investigator will select the chemotherapy in accordance with the protocol defined requirements. The possible choices as defined by the protocol: * Paclitaxel * Gemcitabine * Pegylated liposomal doxorubicin (PLD) * Topotecan The selected chemotherapy will be administered intravenously |
| Azenosertib | DRUG | Azenosertib 400 mg will be administered orally. |
Inclusion Criteria: 1. Female age ≥ 18 years 2. High-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer 3. Measurable disease per RECIST Version 1.1 4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1 5. The subject's tumor tissue must be positive fo...
Top 20 of 59 competitors
Investigator's choice of Chemotherapy is used as an active control in a Phase 3 study for patients with platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancers that are positive for cyclin E1 protein expression. It is being compared against the investigational drug azenosertib (ZN-c3) in this setting.
Investigator's choice of Chemotherapy is not a single drug made by one company; it refers to a selection of standard chemotherapy regimens chosen by the study investigator. The clinical trial comparing it to azenosertib is sponsored by Zentalis Pharmaceuticals, Inc. (ticker: ZNTL).
Investigator's choice of Chemotherapy is not an investigational drug in development; it serves as the active control arm in a Phase 3 clinical trial. The trial, NCT07546500, is currently recruiting and compares this chemotherapy to the investigational agent azenosertib in ovarian cancer.
Investigator's choice of Chemotherapy is part of one Phase 3 clinical trial, NCT07546500, which is recruiting 420 female patients aged 18 and older. The study is active in the United States, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Poland, South Korea, Spain, and Taiwan.
No, Investigator's choice of Chemotherapy is not the same as azenosertib. Azenosertib (ZN-c3) is the investigational drug being tested in the Phase 3 trial, while Investigator's choice of Chemotherapy is the standard-of-care control arm that azenosertib is being compared against in patients with platinum-resistant ovarian cancer.